In the context of pharmacology, what is the primary function of donepezil as an acetylcholinesterase inhibitor?

• A. Decrease acetylcholine release
• B. Compete with acetylcholine at receptors
• C. Increase the duration of acetylcholine action
• D. Enhance the breakdown of acetylcholine

Answer: (C)

Donepezil acts as an acetylcholinesterase inhibitor primarily by increasing the duration of acetylcholine action in the synaptic cleft. Acetylcholinesterase is an enzyme responsible for breaking down acetylcholine into acetate and choline, thereby terminating its action. When donepezil inhibits this enzyme, the breakdown of acetylcholine is reduced, leading to an accumulation of acetylcholine. As a result, acetylcholine remains available to bind to its receptors for a longer period, enhancing cholinergic neurotransmission. This mechanism is particularly beneficial in patients with Alzheimer's disease, where cholinergic deficits contribute to cognitive decline.

This action directly contrasts with the other options. Decreasing acetylcholine release or enhancing its breakdown would lead to reduced cholinergic activity, while competing with acetylcholine at receptors would not explain how donepezil prolongs the effects of acetylcholine in the synaptic cleft. Thus, increasing the duration of acetylcholine action accurately describes donepezil's primary mechanism.